drugset / Trial / NCT03059537

Validation of Stimulated ∆FGF19 for Diagnosing Bile Acid Diarrhoea

NCT03059537

Phase 4 Completed 71 enrolled Lars Kristian Munck
NaSingle-groupOpen-labelDiagnostic

Summary

This study aims to validate a possible diagnostic test for bile acid diarrhoea prospectively compared to the SeHCAT scintigraphy. Fasting participants are given a standard meal and 1,250 mg chenodeoxycholic acid. The investigators measure fasting FGF19, bile acids species including 7-alpha-CHO and serial blood samples after the stimulation.

Timeline

Start
2017-03-13
Primary completion
2017-11-27
Completion
2017-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Chenodeoxycholic Acid Small molecule 1250 mg Oral